These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6671459)

  • 1. Glucagon degradation in fraction of big plasma glucagon in rats treated with carbon tetrachloride.
    Tsubouchi H; Gohda E; Miyazaki H; Kamibeppu A; Oka H; Nagahama J; Hirono S; Fujisaki K; Nakamura O; Daikuhara Y
    Endocrinol Jpn; 1983 Aug; 30(4):577-83. PubMed ID: 6671459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Degradation of [125I]iodoglucagon by normal rat plasma in radioimmunoassay mixture containing aprotinin and its prevention by p-chloromercuriphenyl sulfonate and leupeptin.
    Tsubouchi H; Miyazaki H; Gohda E; Nakayama H; Nakazono Y; Daikuhara Y; Hashimoto S
    Endocrinology; 1986 Sep; 119(3):1137-45. PubMed ID: 2426096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoreactive glucagon in the vascular walls of the rat.
    Tanaka J; Shiosaka S; Tsubouchi H; Gohda E; Daikuhara Y; Tohyama M
    Life Sci; 1983 Oct; 33(16):1599-604. PubMed ID: 6355735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Size heterogeneity of immunoreactive glucagon during bile-duct obstruction in the rabbit.
    Sanke T
    Endocrinol Jpn; 1982 Oct; 29(5):541-51. PubMed ID: 6763562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the liver in glucagon metabolism.
    Jaspan JB; Huen AH; Morley CG; Moossa AR; Rubenstein AH
    J Clin Invest; 1977 Aug; 60(2):421-8. PubMed ID: 874100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic extraction of plasma immunoreactive glucagon components. Predilection for 3500-dalton glucagon metabolism by the liver.
    Jaspan JB; Polonsky KS; Röjdmark S; Ishida T; Field JB; Rubenstein AH
    Diabetes; 1981 Sep; 30(9):767-72. PubMed ID: 7262472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of plasma glucagon. Circulating components in normal subjects and patients with chronic renal failure.
    Kuku SF; Jaspan JB; Emmanouel DS; Zeidler A; Katz AI; Rubenstein AH
    J Clin Invest; 1976 Sep; 58(3):742-50. PubMed ID: 956399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Glucagon degrading activity].
    Wakasugi K
    Nihon Naibunpi Gakkai Zasshi; 1989 May; 65(5):483-96. PubMed ID: 2476336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement and partial characterization of immunoreactive glucagon in gastrointestinal tissues of dogs.
    Morita S; Doi K; Yip CC; Vranic M
    Diabetes; 1976 Nov; 25(11):1018-25. PubMed ID: 186345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Degradation of 125I-glucagon, -pancreatic polypeptide and -insulin by acid saline extract of rat submaxillary gland and their protection by proteinase inhibitors.
    Tasaka Y; Marumo K; Inoue Y; Hirata Y
    Endocrinol Jpn; 1989 Feb; 36(1):47-53. PubMed ID: 2543548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic characterization of plasma glucagon components in a patient with malignant glucagonoma.
    Tanaka K; Watabe T; Shimizu N; Horiuchi T; Nakamura K; Yoshida H
    Metabolism; 1984 Aug; 33(8):728-33. PubMed ID: 6087085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrepancy of fasting plasma glucagon levels measured by different glucagon antisera.
    Tahara Y; Tanaka A; Yamamoto Y; Fukuda M; Kumahara Y; Shima K
    Diabetes Res; 1988 Apr; 7(4):179-83. PubMed ID: 3402167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case with glucagonoma syndrome--heterogeneity of glucagon and insulin.
    Fukushima H; Yamaguchi K; Uzawa H
    Endocrinol Jpn; 1981 Oct; 28(5):575-82. PubMed ID: 6284494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redundant parasympathetic and sympathoadrenal mediation of increased glucagon secretion during insulin-induced hypoglycemia in conscious rats.
    Havel PJ; Parry SJ; Stern JS; Akpan JO; Gingerich RL; Taborsky GJ; Curry DL
    Metabolism; 1994 Jul; 43(7):860-6. PubMed ID: 8028509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salivary gland glucagon is a fictitious substance due to tracer-degrading activity resistant to protease inhibitors.
    Tahara Y; Shima K; Hirota M; Ikegami H; Tanaka A; Kumahara Y
    Biochem Biophys Res Commun; 1983 May; 113(1):340-7. PubMed ID: 6407481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Properties of immunoreactive glucagon fractions of canine stomach and pancreas.
    Srikant CB; McCorkle K; Unger RH
    J Biol Chem; 1977 Mar; 252(6):1847-51. PubMed ID: 191445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purification and characterization of a rat liver cytosol neutral thiol peptidase that degrades glucagon, insulin, and isolated insulin A and B chains.
    Shroyer LA; Varandani PT
    Arch Biochem Biophys; 1985 Jan; 236(1):205-19. PubMed ID: 3881083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of a "big plasma glucagon" response during arginine stimulation of glucagon secretion.
    von Schenck H; Vasquez B; Unger RH
    Horm Metab Res; 1982 Feb; 14(2):69-71. PubMed ID: 7068099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential immunoreactivity of plasma glucagon components in man: studies with different glucagon antibodies.
    Soybel D; Jaspan J; Polonsky K; Goldberg I; Rayfield E; Tager H
    J Clin Endocrinol Metab; 1983 Mar; 56(3):612-8. PubMed ID: 6185527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identical biological effects of pancreatic glucagon and a purified moiety of canine gastric immunoreactive glucagon.
    Doi K; Prentki M; Yip C; Muller WA; Jeanrenaud B; Vranic M
    J Clin Invest; 1979 Mar; 63(3):525-31. PubMed ID: 429572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.